ICON Public (NASDAQ:ICLR) Updates FY24 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $15.00-$15.20 for the period, compared to the consensus EPS estimate of $15.07. The company issued revenue guidance of $8.45-$8.55 billion, compared to the consensus revenue estimate of $8.64 billion.

ICON Public Stock Performance

NASDAQ ICLR traded up $10.36 on Friday, hitting $323.46. 908,602 shares of the company’s stock were exchanged, compared to its average volume of 788,375. The firm has a market cap of $26.69 billion, a price-to-earnings ratio of 39.35, a P/E/G ratio of 1.40 and a beta of 1.23. The firm’s 50-day moving average price is $322.17 and its two-hundred day moving average price is $308.60. ICON Public has a fifty-two week low of $221.20 and a fifty-two week high of $347.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.21.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 earnings per share for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the prior year, the company posted $2.96 earnings per share. ICON Public’s quarterly revenue was up 4.1% on a year-over-year basis. On average, research analysts expect that ICON Public will post 14.54 EPS for the current year.

Wall Street Analyst Weigh In

ICLR has been the subject of several recent analyst reports. Barclays reduced their price objective on shares of ICON Public from $355.00 to $350.00 and set an overweight rating for the company in a research note on Friday. Robert W. Baird upped their price target on ICON Public from $367.00 to $376.00 and gave the stock an outperform rating in a report on Monday, July 8th. TD Cowen raised their price objective on ICON Public from $349.00 to $373.00 and gave the company a buy rating in a research note on Friday, May 31st. William Blair reiterated an outperform rating on shares of ICON Public in a research report on Friday, May 31st. Finally, Evercore ISI dropped their price target on ICON Public from $350.00 to $330.00 and set an outperform rating for the company in a research report on Friday, April 26th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $352.56.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.